Rhythm Pharmaceuticals Croissance future
Future contrôle des critères 5/6
Rhythm Pharmaceuticals devrait augmenter ses bénéfices et son chiffre d'affaires de 62.9% et de 44% par an respectivement. Le BPA devrait croître de de 62.9% par an. Le rendement des capitaux propres devrait être -132.7% dans 3 ans.
Informations clés
62.9%
Taux de croissance des bénéfices
62.9%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 27.1% |
| Taux de croissance des recettes | 44.0% |
| Rendement futur des capitaux propres | -132.7% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 04 Nov 2024 |
Mises à jour récentes de la croissance future
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates
May 09
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22
Mar 03Recent updates
Is Rhythm Pharmaceuticals (NASDAQ:RYTM) Using Debt Sensibly?
Sep 23Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck
Sep 22Rhythm: Pivotal Moment Approaching In Hypothalamic Obesity (Rating Upgrade)
Aug 29Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)
Jun 12Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates
May 09Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares May Have Run Too Fast Too Soon
May 05Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22
Mar 03Rhythm Pharmaceuticals: Action Too Specific
Feb 23Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price
Jan 08We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely
Nov 03We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate
Jul 23Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Popularity With Investors Is Under Threat From Overpricing
Jun 17Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates
May 05Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans
Apr 01An Intrinsic Calculation For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Suggests It's 46% Undervalued
Dec 15We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Needs To Drive Business Growth Carefully
Oct 24Rhythm Pharmaceuticals: Revisiting The Investment Thesis
Oct 10Rhythm Pharmaceuticals announces $100M stock offering; shares fall 12% after hours
Sep 14Rhythm Pharma's Imcivree drug gets expanded approval by European Commission for BBS
Sep 06Industry Analysts Just Made An Incredible Upgrade To Their Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Revenue Forecasts
Aug 08Rhythm Pharmaceuticals Q2 2022 Earnings Preview
Aug 01Rhythm Pharma gains as NICE recommends obesity drug
Jul 18Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 331 | -54 | 1 | 31 | 8 |
| 12/31/2025 | 179 | -173 | -153 | -91 | 10 |
| 12/31/2024 | 123 | -271 | -279 | -140 | 10 |
| 6/30/2024 | 102 | -261 | -169 | -128 | N/A |
| 3/31/2024 | 92 | -274 | -182 | -140 | N/A |
| 12/31/2023 | 77 | -185 | -142 | -136 | N/A |
| 9/30/2023 | 62 | -186 | -146 | -141 | N/A |
| 6/30/2023 | 44 | -182 | -164 | -159 | N/A |
| 3/31/2023 | 34 | -181 | -161 | -156 | N/A |
| 12/31/2022 | 24 | -181 | -174 | -173 | N/A |
| 9/30/2022 | 17 | -181 | -173 | -180 | N/A |
| 6/30/2022 | 13 | -176 | -166 | -173 | N/A |
| 3/31/2022 | 5 | -166 | -160 | -166 | N/A |
| 12/31/2021 | 3 | -70 | -139 | -146 | N/A |
| 9/30/2021 | 1 | -62 | -135 | -135 | N/A |
| 6/30/2021 | 0 | -60 | -122 | -122 | N/A |
| 3/31/2021 | 0 | -56 | -120 | -119 | N/A |
| 12/31/2020 | N/A | -134 | -122 | -122 | N/A |
| 9/30/2020 | N/A | -132 | -125 | -125 | N/A |
| 6/30/2020 | N/A | -134 | -132 | -132 | N/A |
| 3/31/2020 | N/A | -146 | -130 | -127 | N/A |
| 12/31/2019 | N/A | -141 | -126 | -123 | N/A |
| 9/30/2019 | N/A | -133 | -115 | -112 | N/A |
| 6/30/2019 | N/A | -115 | -99 | -95 | N/A |
| 3/31/2019 | N/A | -87 | -83 | -82 | N/A |
| 12/31/2018 | N/A | -74 | -63 | -62 | N/A |
| 9/30/2018 | N/A | -59 | -49 | -49 | N/A |
| 6/30/2018 | N/A | -53 | -41 | -40 | N/A |
| 3/31/2018 | N/A | -47 | N/A | -34 | N/A |
| 12/31/2017 | N/A | -38 | N/A | -29 | N/A |
| 9/30/2017 | N/A | -36 | N/A | -28 | N/A |
| 6/30/2017 | N/A | -32 | N/A | -24 | N/A |
| 3/31/2017 | N/A | -30 | N/A | -24 | N/A |
| 12/31/2016 | N/A | -29 | N/A | -23 | N/A |
| 9/30/2016 | N/A | -27 | N/A | -21 | N/A |
| 6/30/2016 | N/A | -23 | N/A | -18 | N/A |
| 3/31/2016 | N/A | -17 | N/A | -13 | N/A |
| 12/31/2015 | N/A | -12 | N/A | -7 | N/A |
| 9/30/2015 | N/A | -6 | N/A | -4 | N/A |
| 6/30/2015 | N/A | -3 | N/A | -4 | N/A |
| 3/31/2015 | N/A | -5 | N/A | -6 | N/A |
| 12/31/2014 | N/A | -6 | N/A | -8 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: RYTM devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance plus rapide que le taux d'épargne ( 2.5% ).
Bénéfices vs marché: RYTM devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance supérieure à la moyenne du marché.
Croissance élevée des bénéfices: RYTM devrait devenir rentable dans les 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de RYTM ( 44% par an) devrait croître plus rapidement que le marché US ( 8.9% par an).
Croissance élevée des revenus: Le chiffre d'affaires de RYTM ( 44% par an) devrait croître plus rapidement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: RYTM devrait être non rentable dans 3 ans.